Darifenacin Tablet, Extended Release
Product Images NDC 13668-202

9 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 13668-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of darifenacin showing its molecular composition and arrangement as depicted in the image.*
FDA Label Image

Figure1 (Figure 1)

Figure1 (Figure 1)
A line graph showing mean darifenacin plasma concentration (ng/mL) over 24 hours post-dose for two oral extended-release tablet strengths (7.5 mg and 15 mg). The 15 mg dose has higher plasma concentrations throughout, with error bars indicating standard deviation at each time point.*
FDA Label Image

Figure 2a Study 1 (Figure2a Study1)

Figure 2a Study 1 (Figure2a Study1)
A line graph depicting the median reduction and 95 percent confidence interval in incontinence episodes per week from baseline over 12 weeks in a study comparing Darifenacin 7.5 mg, Darifenacin 15 mg, and placebo. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction in episodes. Darifenacin 15 mg shows the greatest reduction, followed by Darifenacin 7.5 mg, with placebo showing the least reduction.*
FDA Label Image

Figure 2b Study 2 (Figure2b Study2)

Figure 2b Study 2 (Figure2b Study2)
A line graph showing median reduction of incontinence episodes per week over 12 weeks for Darifenacin extended release tablets at 7.5 mg and 15 mg doses compared to placebo. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction from baseline, with Darifenacin groups demonstrating greater decreases than placebo.*
FDA Label Image

Figure 2c Study 3 (Figure2c Study3)

Figure 2c Study 3 (Figure2c Study3)
A line graph showing median reduction in incontinence episodes per week from baseline over 12 weeks, comparing Darifenacin 15 mg and placebo. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction values with error bars indicating 95% confidence intervals. The Darifenacin 15 mg line (solid squares) shows a greater reduction compared to placebo (open circles).*
FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo (Logo2)

FDA Label Image

7.5mg30counts (Darifenaciner 7.5mg 30tablets)

7.5mg30counts (Darifenaciner 7.5mg 30tablets)
Label for Darifenacin Extended-Release Tablets 7.5 mg, containing 30 tablets. The label shows NDC 13668-202-30 and is from Torrent Pharmaceuticals Limited. It includes storage instructions, dosage form as extended-release tablets, and note that the product is prescription only (Rx only).*
FDA Label Image

15mg30counts (Darifenaciner 15mg 30tablets)

15mg30counts (Darifenaciner 15mg 30tablets)
Label for Darifenacin Extended-Release Tablets, 15 mg, oral tablets in a bottle of 30 tablets. The label includes storage instructions, warnings, and manufacturer information for Torrent Pharmaceuticals Limited. The NDC number 13668-203-30 is displayed alongside a barcode. The product is prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.